By Investigative Health Correspondent
Published: June 30, 2026
In the modern medical landscape, the ability to peer into our genetic futures has transformed from science fiction into a routine clinical tool. However, as genetic testing for hereditary cancers becomes more accessible, a new and complex demographic has emerged: the "previvor." A portmanteau of "pre-cancer" and "survivor," the term describes individuals who carry a genetic predisposition to cancer—such as a BRCA1 or BRCA2 mutation—but have not yet received a diagnosis.
While the medical community has made significant strides in surgical and surveillance protocols for this group, a critical gap remains in addressing their psychological well-being. Laura Schneebaum, LMHC-D, LPC, NCC, a prominent therapist specializing in hereditary cancer, argues that the mental health challenges faced by previvors are frequently overlooked by the broader clinical community, leaving thousands to navigate a "liminal space" of anxiety and isolation.
Main Facts: The Invisible Struggle of the High-Risk Individual
The term "previvor" was first coined to give a name to a unique experience: living with the knowledge of an impending threat that may or may not materialize. Unlike cancer patients, who have a clear diagnosis and treatment plan, previvors live in a state of perpetual surveillance. This status brings a specific set of psychological stressors that differ significantly from those of the general population or even those of cancer survivors.
According to Schneebaum, the core of the previvor’s struggle lies in the "unseen" nature of their condition. "Many aspects of being a previvor are unseen by others and can leave individuals feeling anxious, alone, overwhelmed, or isolated," she notes. The trauma is often anticipatory. Previvors must make life-altering decisions regarding prophylactic surgeries—such as bilateral mastectomies or oophorectomies—often in their 20s or 30s, long before they feel "ready" to face such medical interventions.
The lack of specialized mental health support is a growing concern. While oncology departments are increasingly integrating social workers and psychologists, these resources are typically reserved for those already in treatment. Previvors, who may spend decades in high-risk screening programs, often find themselves without a roadmap for the emotional toll of "scanxiety"—the debilitating anxiety that precedes regular MRI or mammogram screenings.
Chronology: From Gene Discovery to the Previvor Movement
The journey of the previvor community is inextricably linked to the evolution of genomic medicine over the last three decades:
- The Mid-1990s: The discovery of the BRCA1 and BRCA2 genes revolutionized oncology. For the first time, families with a history of breast and ovarian cancer had a definitive explanation for their lineage of illness.
- 2000: The term "previvor" was officially coined by the organization FORCE (Facing Our Risk of Cancer Empowered). It was born out of a need for a community identity that wasn’t "patient" but wasn’t exactly "healthy" either.
- 2013: The "Angelina Jolie Effect": When the Oscar-winning actress published her op-ed, "My Medical Choice," in The New York Times, detailing her decision to undergo a preventive double mastectomy due to a BRCA1 mutation, global awareness skyrocketed. Referrals for genetic testing increased by nearly 40% in the months following the announcement.
- 2015–2020: The rise of multi-gene panel testing. Scientists identified additional genes (PALB2, CHEK2, ATM) that increased cancer risk, expanding the previvor population beyond the well-known BRCA mutations.
- 2024–2026: A shift toward "Precision Mental Health." Experts like Laura Schneebaum began advocating for specialized therapeutic frameworks that address the specific nuances of genetic risk, moving beyond general grief or anxiety counseling.
Supporting Data: The Statistical Weight of Risk
The psychological burden of previvorship is backed by sobering statistics. A woman with a BRCA1 mutation has up to a 72% lifetime risk of developing breast cancer and a 44% risk of ovarian cancer. In contrast, the general population’s risk for breast cancer is approximately 12%.
Studies have shown that:
- Anticipatory Trauma: Up to 25% of individuals waiting for genetic test results or undergoing high-risk surveillance report symptoms consistent with Post-Traumatic Stress Disorder (PTSD).
- Decision Fatigue: 60% of previvors report significant distress regarding the timing of preventive surgeries, often struggling to balance family planning with cancer risk reduction.
- The "Waiting Room" Effect: Research conducted by organizations like Sharsheret indicates that the periods between screenings are characterized by "cyclical grief"—a phenomenon where the individual mourns their health and bodily autonomy every six to twelve months during the screening cycle.
Furthermore, the financial and social implications add a layer of complexity. The cost of prophylactic surgery and the subsequent recovery time can lead to professional setbacks, while the "unseen" nature of the risk often results in a lack of empathy from employers or peers who may view preventive measures as elective rather than life-saving.
Official Responses: Expert Insights and Support Systems
In response to the growing need for specialized care, organizations like Sharsheret—a national non-profit supporting Jewish women and families facing breast and ovarian cancer—have developed dedicated resources. Their "Waiting Room" initiative is a direct response to the "fear of the unknown" that Schneebaum identifies as a primary trigger for previvor anxiety.
Schneebaum offers four foundational suggestions for previvors to manage their mental health, which can be personalized to fit individual needs:
- Validation of the "Liminal Space": Recognizing that it is normal to feel "in-between." Previvors are not patients, but they are not "unaffected." Acknowledging this unique identity is the first step in reducing isolation.
- Strategic Boundary Setting: Previvors are often inundated with medical data and family opinions. Setting boundaries around when and how they engage with cancer-related information is crucial for maintaining a sense of agency.
- Community Connection: Engaging with peer-led support groups where the "previvor" language is understood. This reduces the burden of having to explain one’s medical choices to those who may not understand the stakes.
- Professional Specialization: Seeking out therapists who understand the specific vocabulary of hereditary cancer. As Schneebaum notes, general therapy may not always address the existential dread associated with a genetic "ticking clock."
The importance of these resources is underscored by the support of major pharmaceutical entities like AstraZeneca and Merck, who have recognized that the journey of the high-risk patient is a lifelong commitment, requiring more than just medical intervention.
Implications: The Future of High-Risk Healthcare
The implications of the previvor movement extend far into the future of healthcare policy and medical ethics. As we move toward a world where whole-genome sequencing may become a standard part of neonatal or early-adulthood care, the previvor population is expected to grow exponentially.
1. The Integration of "Psych-Oncology":
There is a growing demand for the integration of mental health professionals directly into genetic counseling offices. The current model often separates the "data" (the genetic test result) from the "emotional fallout." Future protocols will likely require a mental health assessment as a standard part of the genetic testing pipeline.
2. Insurance and Advocacy:
As previvors advocate for their mental health, insurance companies are being pressured to cover specialized therapy under the umbrella of "preventive care." If a double mastectomy is covered as a preventive measure, proponents argue that the therapy required to process that decision should be equally accessible.
3. The Generational Shift:
We are seeing a shift in how families discuss hereditary risk. The "shame" or "secrecy" often associated with cancer in previous generations is being replaced by a culture of proactive health management. However, this also means younger generations are carrying the burden of their genetic status for longer periods of their lives.
4. Ethical Considerations in Reproductive Health:
With the advent of PGT-M (Preimplantation Genetic Testing for Monogenic disorders), previvors now face the ethical weight of deciding whether to "edit out" these mutations from future generations. This adds a layer of "moral anxiety" that requires deep psychological support.
In conclusion, the work of professionals like Laura Schneebaum and organizations like Sharsheret highlights a pivotal truth in modern medicine: knowing our risk is only half the battle. The other half is learning how to live with that knowledge. As the previvor community continues to find its voice, the medical establishment must listen, ensuring that the "waiting room" is no longer a place of isolated fear, but a space of supported transition.
About the Author
